Toluene has antidepressant-like actions in two animal models used for the screening of antidepressant drugs

Cruz, Silvia L.; Soberanes-Chávez, Paulina; Páez-Martínez, Nayeli; López‐Rubalcava, Carolina

doi:10.1007/s00213-009-1462-2

Cited by 28 publications

(15 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice were submitted to behavioral testing 30 min later. The dose and time point of ketamine administration were selected on the basis of previous results from our laboratory (Mantovani et al 2003;Bettio et al 2012;Ludka et al 2013) and others (Cruz et al 2009;Iijima et al 2012).…”

Section: Involvement Of Nmda Receptors In the Anti-immobility Effect mentioning

confidence: 99%

The modulation of NMDA receptors and l-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test

et al. 2015

View full text Add to dashboard Cite

The modulation of N-methyl-D-aspartate receptor (NMDAR) and L-arginine/nitric oxide (NO) pathway is a therapeutic strategy for treating depression and neurologic disorders that involves excitotoxicity. Literature data have reported that creatine exhibits antidepressant and neuroprotective effects, but the implication of NMDAR and L-arginine/nitric oxide (NO) pathway in these effects is not established. This study evaluated the influence of pharmacological agents that modulate NMDAR/L-arginine-NO pathway in the anti-immobility effect of creatine in the tail suspension test (TST) in mice. The NOx levels and cellular viability in hippocampal and cerebrocortical slices of creatine-treated mice were also evaluated. The anti-immobility effect of creatine (10 mg/kg, po) in the TST was abolished by NMDA (0.1 pmol/mouse, icv), D-serine (30 µg/mouse, icv, glycine-site NMDAR agonist), arcaine (1 mg/kg, ip, polyamine site NMDAR antagonist), L-arginine (750 mg/kg, ip, NO precursor), SNAP (25 μg/mouse, icv, NO donor), L-NAME (175 mg/kg, ip, non-selective NOS inhibitor) or 7-nitroindazole (50 mg/kg, ip, neuronal NOS inhibitor), but not by DNQX (2.5 µg/mouse, icv, AMPA receptor antagonist). The combined administration of sub-effective doses of creatine (0.01 mg/kg, po) and NMDAR antagonists MK-801 (0.001 mg/kg, po) or ketamine (0.1 mg/kg, ip) reduced immobility time in the TST. Creatine (10 mg/kg, po) increased cellular viability in hippocampal and cerebrocortical slices and enhanced hippocampal and cerebrocortical NO x levels, an effect potentiated by L-arginine or SNAP and abolished by 7-nitroindazole or L-NAME. In conclusion, the anti-immobility effect of creatine in the TST involves NMDAR inhibition and enhancement of NO levels accompanied by an increase in neural viability.

show abstract

Section: Involvement Of Nmda Receptors In the Anti-immobility Effect mentioning

confidence: 99%

The modulation of NMDA receptors and l-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test

et al. 2015

View full text Add to dashboard Cite

show abstract

“…TST has predictive validity because it measures antidepressant-like responses from various classes of drugs. Ketamine reduces immobility levels in mice acutely, with studies reporting reductions in immobility time at 30 min (Mantovani et al, 2003; Rosa et al, 2003; Cruz et al, 2009; Koike et al, 2011a) and 24 h (Koike et al, 2011b) following a single injection of ketamine.…”

Section: Antidepressant-like Behavioral Effects Of Ketamine In Rodentsmentioning

confidence: 99%

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

2013

View full text Add to dashboard Cite

Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant because it acts rapidly and is effective for treatment-resistant patients. A single infusion of ketamine alleviates depressive symptoms in treatment-resistant depressed patients within hours and these effects may be sustained for up to 2 weeks. Although the discovery of ketamine's effects has reshaped drug discovery for antidepressants, the psychotomimetic properties of this compound limit the use of this therapy to the most severely ill patients. In order to develop additional antidepressants like ketamine, adequate preclinical behavioral screening paradigms for fast-acting antidepressants need to be established and used to identify the underlying neural mechanisms. This review examines the preclinical literature attempting to model the antidepressant-like effects of ketamine. Acute administration of ketamine has produced effects in behavioral screens for antidepressants like the forced swim test, novelty suppression of feeding and in rodent models for depression. Protracted behavioral effects of ketamine have been reported to appear after a single treatment that last for days. This temporal pattern is similar to its clinical effects and may serve as a new animal paradigm for rapid antidepressant effects in humans. In addition, protracted changes in molecules mediating synaptic plasticity have been implicated in mediating the antidepressant-like behavioral effects of ketamine. Current preclinical studies are examining compounds with more specific pharmacological effects at glutamate receptors and synapses in order to develop additional rapidly acting antidepressants without the hallucinogenic side effects or abuse potential of ketamine.

show abstract

“…The antidepressant effect of toluene was tested on two animal models capable of screening possible antidepressants. Toluene exerted concentration-dependent antidepressant effect (Cruz et al 2009). Páez-Martinez et al investigated a single toluene exposure in connection with morphine administration.…”

Section: Benzene and Alkylbenzenesmentioning

confidence: 99%

Finding possible pharmacological effects of identified organic compounds in medicinal waters (BTEX and phenolic compounds)

Szabó

Varga

2019

Int J Biometeorol

View full text Add to dashboard Cite

Medicinal thermal waters consist of a mixture of different organic and inorganic compounds. Traditionally, these waters are only characterized and classified by their inorganic composition; however, the bioavailability of the majority of these inorganic compounds is limited. Many authors investigate the organic fractions of thermal waters. These authors propose that these compounds have a potential effect on health. To elucidate the underlying mechanisms, it is crucial to know the composition of the organic fractions. The absorption of these compounds on intact skin or mucosa is notable. Some of them have local anaesthetic effect or affect receptors in the central nervous system. In the knowledge of the chemical composition, we are able to estimate the possible pharmacological effect or might be able to assess possible toxicity risks. In the present article, we aim to review possible health effects of two of the identified organic fractions: benzene and alkylbenzenes and phenolic compounds that might correlate with the therapeutic effect on rheumatological or other diseases.

show abstract

Toluene has antidepressant-like actions in two animal models used for the screening of antidepressant drugs

Abstract: Toluene has antidepressant-like effects that are synergized with NMDA receptor antagonists.

Cited by 28 publications

References 53 publications

The modulation of NMDA receptors and l-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test

The modulation of NMDA receptors and l-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Finding possible pharmacological effects of identified organic compounds in medicinal waters (BTEX and phenolic compounds)

Contact Info

Product

Resources

About